599 related articles for article (PubMed ID: 33053763)
1. Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features.
Kim HJ; Kim DY
Molecules; 2020 Oct; 25(20):. PubMed ID: 33053763
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Immune Cell Therapy for Glioblastoma.
Kang X; Zheng Y; Hong W; Chen X; Li H; Huang B; Huang Z; Tang H; Geng W
Front Immunol; 2020; 11():544563. PubMed ID: 33193310
[TBL] [Abstract][Full Text] [Related]
3. A contemporary update on glioblastoma: molecular biology, current management, and a vision towards bio-adaptable personalized care.
Habib A; Pease M; Kodavali CV; Amankulor N; Zinn PO
J Neurooncol; 2021 Jan; 151(2):103-112. PubMed ID: 33394264
[TBL] [Abstract][Full Text] [Related]
4. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
5. Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches.
Miranda A; Blanco-Prieto M; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):372-388. PubMed ID: 28755993
[TBL] [Abstract][Full Text] [Related]
6. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
7. Understanding glioblastoma tumor biology: the potential to improve current diagnosis and treatments.
Kesari S
Semin Oncol; 2011 Dec; 38 Suppl 4():S2-10. PubMed ID: 22078644
[TBL] [Abstract][Full Text] [Related]
8. Adult Glioblastoma.
Alexander BM; Cloughesy TF
J Clin Oncol; 2017 Jul; 35(21):2402-2409. PubMed ID: 28640706
[TBL] [Abstract][Full Text] [Related]
9. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
[TBL] [Abstract][Full Text] [Related]
10. Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches.
Gilbert MR
Semin Oncol; 2011 Dec; 38 Suppl 4():S21-33. PubMed ID: 22078645
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
Trials; 2018 May; 19(1):293. PubMed ID: 29801515
[TBL] [Abstract][Full Text] [Related]
12. Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review).
Bryukhovetskiy I; Ponomarenko A; Lyakhova I; Zaitsev S; Zayats Y; Korneyko M; Eliseikina M; Mischenko P; Shevchenko V; Shanker Sharma H; Sharma A; Khotimchenko Y
Int J Mol Med; 2018 Aug; 42(2):691-702. PubMed ID: 29749540
[TBL] [Abstract][Full Text] [Related]
13. Emerging extracellular vesicle-based carriers for glioblastoma diagnosis and therapy.
Wang J; Liu Y; Liu F; Gan S; Roy S; Hasan I; Zhang B; Guo B
Nanoscale; 2023 Jul; 15(26):10904-10938. PubMed ID: 37337814
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms regulating glioma invasion.
Paw I; Carpenter RC; Watabe K; Debinski W; Lo HW
Cancer Lett; 2015 Jun; 362(1):1-7. PubMed ID: 25796440
[TBL] [Abstract][Full Text] [Related]
15. Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment
Yang J; Shi Z; Liu R; Wu Y; Zhang X
Theranostics; 2020; 10(7):3223-3239. PubMed ID: 32194864
[TBL] [Abstract][Full Text] [Related]
16. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges.
Nicholas MK; Lukas RV; Chmura S; Yamini B; Lesniak M; Pytel P
Semin Oncol; 2011 Apr; 38(2):243-53. PubMed ID: 21421114
[TBL] [Abstract][Full Text] [Related]
17. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
18. Advances in immunotherapy for the treatment of glioblastoma.
Tivnan A; Heilinger T; Lavelle EC; Prehn JH
J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapeutic targets and agents for glioblastoma migrating cells.
Di C; Mattox AK; Harward S; Adamson C
Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
[TBL] [Abstract][Full Text] [Related]
20. Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside.
Li Y; Sharma A; Maciaczyk J; Schmidt-Wolf IGH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]